Cue Health's COVID-19 self-test approved in Singapore » 09:1912/0112/01/21
Cue Health received…
Cue Health received Pandemic Special Access Route authorization from the Health Sciences Authority for the Cue COVID-19 Test for self-testing in Singapore. The Cue COVID-19 Test is the first natively digital molecular diagnostic product ever authorized for consumer home use in Singapore. Cue's partnership with Omnicell (OMCL) allows Cue to immediately begin supporting public sector use of the Cue COVID-19 Test. Cue intends to explore both public and private sector partnerships that Cue believes will further enable the complete utilization of the Cue Health Monitoring System for not only the Cue COVID-19 Test, but also Cue's future test menu and other offerings.
Cue Health management to meet virtually with BTIG » 12:0811/3011/30/21
Virtual Meeting to be…
Virtual Meeting to be held on December 7 hosted by BTIG.
Cue Health confirms COVID-19 tests can detect Omicron variant » 09:1611/2911/29/21
Cue Health announced it…
Cue Health announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron. Using information from the GISAID database, Cue has determined its COVID-19 tests, which uses molecular, NAAT, technology, can detect the Omicron variant. Specifically, Cue found that 99.2% of the available 127 published sequences are a perfect match to the primers used in the Company's tests. "Our molecular test is backed by the science and technology necessary to detect emerging variants, including Omicron, enabling individuals and healthcare practitioners to make better-informed decisions," said Ayub Khattak, Co-Founder and CEO of Cue. "Fast and accurate testing that is bolstered by a scientist-led surveillance and monitoring system, which identifies and analyzes variants in real time, will continue to play a critical role in producing actionable health data, preventing community spread and driving better outcomes."
|Over a week ago|
Cue Health and Helix partner for COVID-19 variant information solution » 09:2011/1811/18/21
Cue Health and Helix, a…
Cue Health and Helix, a genomics company that provides nationwide viral surveillance of respiratory disease, announced a new collaboration to provide individuals who test positive on Cue's at-home molecular COVID-19 test the opportunity to learn which variant they have contracted as part of a broader research study on the SARS-CoV-2 virus. This collaboration builds on Cue's real-time Variant Tracking and Sequencing Platform, which will utilize AI and ML from Google Cloud. Cue Health and Helix intend to roll out this new capability in Q4. Cue users who receive a positive test result for COVID-19 will be able to opt-in to SARS-CoV-2 variant sequencing. Users will receive a same-day sample collection kit with a prepaid return shipper via Cue's last-mile delivery partners. The Cue Health App will guide users through a swab self-collection to obtain their sample for sequencing. Returned samples will arrive at Helix for processing, and results from Helix will be shared with the individual through the Cue Health App within ten days.
Cue Health sees FY21 revenue $580M-$590M, consensus $541.29M 16:0311/1011/10/21
Cue Health reports Q3 EPS 14c vs (52c) last year » 16:0311/1011/10/21
Reports Q3 revenue…
Reports Q3 revenue $223.7M, consensus $200.3M. "In the last few months, we generated record quarterly revenue while entering the public markets, growing our customer base, readying to launch our direct-to-consumer offering with integrated virtual care and in-app travel proctoring, and expanding our team," said Ayub Khattak, CEO and co-founder of Cue Health. "We're confident we've laid a solid foundation for long-term value creation at Cue and look forward to delivering on our mission of empowering people to live their healthiest lives through personalized, proactive, and informed healthcare."
|Over a month ago|
Cue Health provides molecular COVID-19 testing to MLB Clubs » 09:1611/0111/01/21
Cue Health and Major…
Cue Health and Major League Baseball announced that Cue has been providing all Clubs, as well as the league office, with its integrated Cue platform, which features both the portable Cue Health Monitoring System and easy-to-use Cue COVID-19 tests, throughout the Postseason and World Series. The Cue COVID-19 Test for Home and Over The Counter Use is the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without physician supervision or a prescription. Cue's platform is a molecular diagnostic system that delivers results directly to mobile smart devices - both Android and iOS - in about 20 minutes.
Fly Intel: Top five analyst initiations » 09:5410/1910/19/21
CWAN, HLTH, PENN, FUTU, SRT
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Clearwater Analytics (CWAN) initiated with an Outperform at RBC Capital, William Blair, Credit Suisse, and Oppenheimer, initiated with an Overweight at JPMorgan and Wells Fargo, initiated with a Neutral at Goldman Sachs and Piper Sandler, initiated with an Equal Weight at Morgan Stanley and a Hold at Loop Capital. 2. Cue Health (HLTH) initiated with a Buy at Goldman Sachs, an Outperform at Cowen and an Equal Weight at Morgan Stanley. 3. Penn National (PENN) initiated with a Buy at Berenberg. 4. Futu Holdings (FUTU) initiated with a Buy at CLSA. 5. StarTek (SRT) initiated with an Outperform at Barrington. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Cue Health initiated with a Buy at BTIG » 09:3010/1910/19/21
BTIG analyst Mark Massaro…
BTIG analyst Mark Massaro initiated coverage of Cue Health with a Buy rating and $18 price target. The analyst views Cue as a "rapidly growing" health technology platform company that is well positioned to take share both from reference labs, other point-of-care testing companies, and help expand the $80B U.S. lab testing market. He highlights its "industry-leading" handheld instrument form-factor, which the analyst says drives "much better" ease of use, particularly when used in people's homes.
Cue Health initiated with an Outperform at Cowen » 08:5610/1910/19/21
As reported previously,…
As reported previously, Cowen analyst Charles Rhyee initiated coverage of Cue Health with an Outperform rating and $14 price target. The analyst said the company offers an innovative testing system that provides the convenience of a consumer electronic device with the accuracy of complex molecular testing platforms, w/ the potential to disrupt the existing diagnostic testing market.